Clinical Trial

Causal Relationship Between Plasma VEGF Family Proteins and Placenta Previa: A Two-Sample Mendelian Randomization Study

Study acronym: VEGF PP
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 1, 2024 (before its estimated November 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
This study aims to investigate the causal relationship between plasma vascular endothelial growth factor (VEGF) family proteins and placenta previa using a two-sample Mendelian randomization (MR) approach. Genome-wide association study (GWAS) data will be analyzed to assess the correlation and potential causality between VEGF protein levels and the occurrence of placenta previa.
Trial Details
NCT Number NCT06620068
Lead Sponsor Guangzhou Institute of Respiratory Disease
Collaborators: The Second People's Hospital of Foshan, First People's Hospital of Foshan, Maternal and Child Health Hospital of Foshan
Conditions Placenta Previa
Enrollment 207,473 participants
Start Date 2024-09-25
Primary Completion 2024-11-01 (estimated)
Study Completion 2024-12-01 (estimated)
Updated on ClinicalTrials.gov 2024-10-01